| Literature DB >> 33387730 |
Eliška Kohelová1, Jana Maříková2, Jan Korábečný3, Daniela Hulcová4, Tomáš Kučera5, Daniel Jun3, Jakub Chlebek1, Jaroslav Jenčo1, Marcela Šafratová4, Martina Hrabinová3, Aneta Ritomská1, Milan Malaník6, Rozálie Peřinová1, Kateřina Breiterová1, Jiří Kuneš2, Lucie Nováková7, Lubomír Opletal1, Lucie Cahlíková8.
Abstract
Twenty known Amaryllidaceae alkaloids of various structural types, and one undescribed alkaloid of narcikachnine-type, named narcieliine (3), have been isolated from fresh bulbs of Zephyranthes citrina. The chemical structures of the isolated alkaloids were elucidated by a combination of MS, HRMS, 1D and 2D NMR, and CD spectroscopic techniques, and by comparison with literature data. The absolute configuration of narcieliine (3) has also been determined. Compounds isolated in a sufficient quantity were evaluated for their in vitro acetylcholinesterase (AChE; E.C. 3.1.1.7), butyrylcholinesterase (BuChE; E.C. 3.1.1.8), and prolyl oligopeptidase (POP; E.C. 3.4.21.26) inhibition activities. Significant human AChE/BuChE (hAChE/hBuChE) inhibitory activity was demonstrated by the newly described alkaloid narcieliine (3), with IC50 values of 18.7 ± 2.3 µM and 1.34 ± 0.31 µM, respectively. This compound is also predicted to cross the blood-brain barrier (BBB) through passive diffusion. The in vitro data were further supported by in silico studies of 3 in the active site of hAChE/hBuChE.Entities:
Keywords: Alkaloids; Alzheimer's disease; Amaryllidaceae; Docking studies; Narcieliine; Zephyranthes citrina
Year: 2020 PMID: 33387730 DOI: 10.1016/j.bioorg.2020.104567
Source DB: PubMed Journal: Bioorg Chem ISSN: 0045-2068 Impact factor: 5.275